| Autor: |
Kraker J; Jessica Kraker, MD University of Maryland, Department of Neurology, 22 South Greene Street, N4W50, Baltimore, MD 21201, USA. jkrak001@umaryland.edu. |
| Jazyk: |
angličtina |
| Zdroj: |
Current treatment options in neurology [Curr Treat Options Neurol] 2009 Jan; Vol. 11 (1), pp. 46-51. |
| DOI: |
10.1007/s11940-009-0007-7 |
| Abstrakt: |
The paraneoplastic syndrome caused by Ma2/Ta antibodies alone (not in conjunction with Ma1 or Ma3 antibodies) varies in presentation from classic limbic encephalitis. The Ma2 syndrome may present with symptoms referable to the brainstem, diencephalon, and limbic system. These clinical symptoms are accompanied by MRI changes and abnormal electroencephalographic findings. It is important to recognize when the encephalitic syndrome is secondary to Ma2 paraneoplastic antibodies, as the patients improve or stabilize most often when the underlying carcinoma is treated. Treatment of the paraneoplastic syndrome begins with recognition of the symptoms, such as memory impairment, seizures, sleep disturbances, bradykinesia or hypokinesia, and eye movement abnormalities. If a primary tumor is discovered during the workup, it should be removed and treated with the most up-to-date oncologic treatment available. In addition to oncologic treatment, the syndrome may be treated with an immunosuppressant regimen to optimize the neurologic outcome. Leaving the patient untreated will result in decline and eventual death from the cancer itself or from complications of the paraneoplastic syndrome. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink